New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
|New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation|
Lancet Haematol. 2023 Jan;10(1): e46-e58.
Watts M J.et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.